25CN-NBOH

25CN-NBOH
Clinical data
Other names	2C-CN-NBOH; NBOH-2C-CN; N-(2-Hydroxybenzyl)-4-cyano-2,5-dimethoxyphenethylamine
Drug class	Selective serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Legal status
Legal status	UK: Class A; Illegal in Hungary;
Identifiers
	IUPAC name 4-[2-[(2-hydroxyphenyl)methylamino]ethyl]-2,5-dimethoxybenzonitrile;
CAS Number	1391489-32-9 ;
PubChem CID	90489020;
ChemSpider	58191431;
UNII	32CN2DQE3Q;
CompTox Dashboard (EPA)	DTXSID301017253 ;
Chemical and physical data
Formula	C18H20N2O3
Molar mass	312.369 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc1cc(C#N)c(OC)cc1CCNCc2ccccc2O;
	InChI InChI=1S/C18H20N2O3/c1-22-17-10-15(11-19)18(23-2)9-13(17)7-8-20-12-14-5-3-4-6-16(14)21/h3-6,9-10,20-21H,7-8,12H2,1-2H3; Key:VWEDZTZAXHMZIL-UHFFFAOYSA-N;

25CN-NBOH, also known as NBOH-2C-CN or as N-(2-hydroxybenzyl)-4-cyano-2,5-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine, 2C, and 25-NB (NBOH) families. It was developed and described in 2011 at the University of Copenhagen.

The drug is one of the most selective agonists of the serotonin 5-HT_2A receptor known. However, findings on its selectivity have varied, with some studies finding as little as 10-fold selectivity for the serotonin 5-HT_2A receptor over the serotonin 5-HT_2C receptor. A much more selective derivative of 25CN-NBOH, TGF-8027, has since been described.

A tritiated version of 25CN-NBOH has also been developed and used for more detailed investigations of the binding to serotonin 5-HT₂ receptors and autoradiography. In 2025, 25CN-NBOH was suggested as a possible alternative and replacement of DOI for use in scientific research.